Stabilization strategies for unstable dynamics.

P. Morasso,M. Casadio,Dalia De Santis,T. Nomura,F. Rea,J. Zenzeri

DOI: https://doi.org/10.1016/j.jelekin.2014.10.006

2014-12-01

Abstract:

What problem does this paper attempt to address?

Identification of Host-Targeted Small Molecules That Restrict Intracellular Mycobacterium tuberculosis Growth

Sarah A. Stanley,Amy K. Barczak,Melanie R. Silvis,Samantha S. Luo,Kimberly Sogi,Martha Vokes,Mark-Anthony Bray,Anne E. Carpenter,Christopher B. Moore,Noman Siddiqi,Eric J. Rubin,Deborah T. Hung

DOI: https://doi.org/10.1371/journal.ppat.1003946

IF: 7.464

2014-02-20

PLoS Pathogens

Abstract:Mycobacterium tuberculosis remains a significant threat to global health. Macrophages are the host cell for M. tuberculosis infection, and although bacteria are able to replicate intracellularly under certain conditions, it is also clear that macrophages are capable of killing M. tuberculosis if appropriately activated. The outcome of infection is determined at least in part by the host-pathogen interaction within the macrophage; however, we lack a complete understanding of which host pathways are critical for bacterial survival and replication. To add to our understanding of the molecular processes involved in intracellular infection, we performed a chemical screen using a high-content microscopic assay to identify small molecules that restrict mycobacterial growth in macrophages by targeting host functions and pathways. The identified host-targeted inhibitors restrict bacterial growth exclusively in the context of macrophage infection and predominantly fall into five categories: G-protein coupled receptor modulators, ion channel inhibitors, membrane transport proteins, anti-inflammatories, and kinase modulators. We found that fluoxetine, a selective serotonin reuptake inhibitor, enhances secretion of pro-inflammatory cytokine TNF-α and induces autophagy in infected macrophages, and gefitinib, an inhibitor of the Epidermal Growth Factor Receptor (EGFR), also activates autophagy and restricts growth. We demonstrate that during infection signaling through EGFR activates a p38 MAPK signaling pathway that prevents macrophages from effectively responding to infection. Inhibition of this pathway using gefitinib during in vivo infection reduces growth of M. tuberculosis in the lungs of infected mice. Our results support the concept that screening for inhibitors using intracellular models results in the identification of tool compounds for probing pathways during in vivo infection and may also result in the identification of new anti-tuberculosis agents that work by modulating host pathways. Given the existing experience with some of our identified compounds for other therapeutic indications, further clinically-directed study of these compounds is merited.

microbiology,virology,parasitology
Identification of bioactive compounds Inhibitors of M. tuberculosis Growth Using Whole Cell Based High-Throughput Screening

Pham Thi Kim Lien,Sang Huyn Cho,Tran Thi Van Phuong,Tran Thi Mai Hung,Vu Thi Mai Anh,Dang Duc Anh

DOI: https://doi.org/10.51403/0868-2836/2022/926

2023-03-10

Tạp chí Y học Dự phòng

Abstract:Drug discovery and development for Mycobacterium tuberculosis (Mtb) has progressed significantly in more than 20 years, although it is still woefully underfunded. From a drug discovery perspective, tuberculosis is a particularly challenging disease. Screening for new antimicrobial agents is routinely conducted only against actively replicating bacteria. However, it is now widely accepted that a physiological state of nonreplicating persistence (NRP) is responsible for antimicrobial tolerance in many bacterial infections. The MICs of 138 established pure bioactive compounds determined in microplate cultures, of which anaerobic conditions were maintained for ten days and, for comparative purposes, aerobic conditions for seven days. Cultures exposed to drugs under anaerobic conditions followed by 28h of “recovery” under ambient oxygen produced a luminescent signal that was, for most compounds, proportional to the number of hits determined > 90% in MICs MABA was 99 (71.7%), GAS was 118 (85.5%), and MICs LORA was 7 (5.1%). As a result, aerobic and anaerobic bacteria conditions in vitro assays are prone to support a drug discovery program for tuberculosis. These potential bioactive compounds are in the drug discovery and development of anti-tubercular drugs.

English Else
Vascular Management During Live Donor Nephrectomy: An Online Survey Among Transplant Surgeons

S. Janki,D. Verver,K. Klop,A. Friedman,T. Peters,L. Ratner,J. Ijzermans,F. Dor

DOI: https://doi.org/10.1111/ajt.13142

IF: 9.369

2015-06-01

American Journal of Transplantation

Abstract:In 2006, a survey from the American Society of Transplant Surgeons disclosed significant and sometimes fatal hemorrhagic events in live donor nephrectomies (LDN) related to failure of clips, leading to the contraindication of the Weck® Hem‐o‐lok® clip for control of the renal artery during LDN. A survey regarding vascular control techniques, their perceived safety ratings and their failures was sent to 645 European Society for Organ Transplantation members who profiled their profession as “surgeon” and selected “kidney” as organ type. Two hundred forty‐three (41%) members responded, of whom 171 (63.3%) independently perform LDN. Their responses were analyzed. For arterial and venous vascular control, the GIA™ and TA™stapler are used most frequently, and were rated the safest. Of the 121 reported hemorrhagic events, slippage and dislodgement of clips occurred at least 58 times, while stapler malfunction occurred at least 40 times. One donor death from hemorrhage related to clip dysfunction was reported. Hemorrhagic complications of LDN with fatal and non‐fatal outcomes still occur. Strikingly, many surgeons do not use the vascular closing technique that they consider most safe. Failure of non‐transfixion techniques is associated with greater risks for the donor. Control of major vessels in LDN must employ transfixion techniques for optimal donor safety.
Radiographic Comparison of Standing Medial Cuneiform Arch Height in Adults With and Without Acquired Flatfoot Deformity

G. Arangio,T. Wasser,Albéric Rogman

DOI: https://doi.org/10.1177/107110070602700813

IF: 3.569

2006-08-01

Foot & Ankle International

Abstract:Background: Adult acquired flatfoot (AAF) is characterized by decreased arch height, talar depression, medial arch depression and elongation, and forefoot abduction. We have measured standing arch height in AAF patients and in a control group of patients using the standing lateral medial cuneiform arch height radiographic measurement. Methods: Fifteen (25 feet) patients were selected with the clinical diagnosis of symptomatic AAF with no secondary diagnoses. A control group consisted of 36 (72 feet) patients with no foot deformities or prior foot surgeries. Arch height was measured in millimeters using the standing medial cuneiform height on the lateral radiographic view. Results: The mean standing medial cuneiform arch height in the control group was 18.38 mm. The mean arch height in the AAF group was 11.04 mm (p < 0.001). There were no differences between right and left feet in the control group or symptomatic and contralateral feet in the AAF group. Body mass index (BMI) in the control group was 26.17 and in the AAF 33.74. (p = 0.007). Conclusion: These data provide a control value for the arch height using the medial cuneiform as reference. The decrease in arch height is a strong indicator of AAF. A study with larger numbers of patients is necessary.
Rapid Gene Silencing Followed by Antimicrobial Susceptibility Testing for Target Validation in Antibiotic Discovery

Chris Daniel,Sam Willcocks,Sanjib Bhakta

DOI: https://doi.org/10.1007/978-1-0716-3981-8_3

Abstract:Mycobacterium tuberculosis is the main causative agent of tuberculosis (TB)-an ancient yet widespread global infectious disease to which 1.6 million people lost their lives in 2021. Antimicrobial resistance (AMR) has been an ongoing crisis for decades; 4.95 million deaths were associated with antibiotic resistance in 2019. While AMR is a multi-faceted problem, drug discovery is an urgent part of the solution and is at the forefront of modern research.The landscape of drug discovery for TB has undoubtedly been transformed by the development of high-throughput gene-silencing techniques that enable interrogation of every gene in the genome, and their relative contribution to fitness, virulence, and AMR. A recent advance in this area is CRISPR interference (CRISPRi). The application of this technique to antimicrobial susceptibility testing (AST) is the subject of ongoing research in basic science.CRISPRi technology can be used in conjunction with the high-throughput SPOT-culture growth inhibition assay (HT-SPOTi) to rapidly evaluate and assess gene essentiality including non-essential, conditionally essential (by using appropriate culture conditions), and essential genes. In addition, the HT-SPOTi method can develop drug susceptibility and drug resistance profiles.This technology is further useful for drug discovery groups who have designed target-based inhibitors rationally and wish to validate the primary mechanisms of their novel compounds' antibiotic action against the proposed target.
A high-throughput target-based screening approach for the identification and assessment of Mycobacterium tuberculosis mycothione reductase inhibitors

Natalia Smiejkowska,Lauren Oorts,Kevin Van Calster,Linda De Vooght,Rob Geens,Henri-Philippe Mattelaer,Koen Augustyns,Sergei V. Strelkov,Dirk Lamprecht,Koen Temmerman,Yann G.-J. Sterckx,Davie Cappoen,Paul Cos

DOI: https://doi.org/10.1128/spectrum.03723-23

IF: 3.7

2024-02-05

Microbiology Spectrum

Abstract:ABSTRACT The World Health Organization’s goal to combat tuberculosis (TB) is hindered by the emergence of anti-microbial resistance, therefore necessitating the exploration of new drug targets. Multidrug regimens are indispensable in TB therapy as they provide synergetic bactericidal effects, shorten treatment duration, and reduce the risk of resistance development. The research within our European RespiriTB consortium explores Mycobacterium tuberculosis energy metabolism to identify new drug candidates that synergize with bedaquiline, with the aim of discovering more efficient combination drug regimens. In this study, we describe the development and validation of a luminescence-coupled, target-based assay for the identification of novel compounds inhibiting Mycobacterium tuberculosis mycothione reductase (Mtr Mtb ), an enzyme with a role in the protection against oxidative stress. Recombinant Mtr Mtb was employed for the development of a highly sensitive, robust high-throughput screening (HTS) assay by coupling enzyme activity to a bioluminescent readout. Its application in a semi-automated setting resulted in the screening of a diverse library of ~130,000 compounds, from which 19 hits were retained after an assessment of their potency, selectivity, and specificity. The selected hits formed two clusters and four fragment molecules, which were further evaluated in whole-cell and intracellular infection assays. The established HTS discovery pipeline offers an opportunity to deliver novel Mtr Mtb inhibitors and lays the foundation for future efforts in developing robust biochemical assays for the identification and triaging of inhibitors from high-throughput library screens. IMPORTANCE The growing anti-microbial resistance poses a global public health threat, impeding progress toward eradicating tuberculosis. Despite decades of active research, there is still a dire need for the discovery of drugs with novel modes of action and exploration of combination drug regimens. Within the European RespiriTB consortium, we explore Mycobacterium tuberculosis energy metabolism to identify new drug candidates that synergize with bedaquiline, with the aim of discovering more efficient combination drug regimens. In this study, we present the development of a high-throughput screening pipeline that led to the identification of M. tuberculosis mycothione reductase inhibitors.

microbiology
A Novel Tool to Identify Bactericidal Compounds against Vulnerable Targets in Drug-Tolerant M. tuberculosis found in Caseum

Jansy P Sarathy,Min Xie,Richard M Jones,Adrienne Chang,Paulina Osiecki,Danielle Weiner,Wen-Shan Tsao,Maureen Dougher,Landry Blanc,Nader Fotouhi,Laura E Via,Clifton E Barry 3rd,Iwijn De Vlaminck,David R Sherman,Véronique A Dartois

DOI: https://doi.org/10.1128/mbio.00598-23

IF: 6.4

2023-04-25

mBio

Abstract:Caseous necrosis is a hallmark of tuberculosis (TB) pathology and creates a niche for drug-tolerant persisters within the host. Cavitary TB and high bacterial burden in caseum require longer treatment duration. An in vitro model that recapitulates the major features of Mycobacterium tuberculosis (Mtb) in caseum would accelerate the identification of compounds with treatment-shortening potential. We have developed a caseum surrogate model consisting of lysed and denatured foamy macrophages. Upon inoculation of Mtb from replicating cultures, the pathogen adapts to the lipid-rich matrix and gradually adopts a nonreplicating state. We determined that the lipid composition of ex vivo caseum and the surrogate matrix are similar. We also observed that Mtb in caseum surrogate accumulates intracellular lipophilic inclusions (ILI), a distinctive characteristic of quiescent and drug-tolerant Mtb. Expression profiling of a representative gene subset revealed common signatures between the models. Comparison of Mtb drug susceptibility in caseum and caseum surrogate revealed that both populations are similarly tolerant to a panel of TB drugs. By screening drug candidates in the surrogate model, we determined that the bedaquiline analogs TBAJ876 and TBAJ587, currently in clinical development, exhibit superior bactericidal against caseum-resident Mtb, both alone and as substitutions for bedaquiline in the bedaquiline-pretomanid-linezolid regimen approved for the treatment of multidrug-resistant TB. In summary, we have developed a physiologically relevant nonreplicating persistence model that reflects the distinct metabolic and drug-tolerant state of Mtb in caseum. IMPORTANCE M. tuberculosis (Mtb) within the caseous core of necrotic granulomas and cavities is extremely drug tolerant and presents a significant hurdle to treatment success and relapse prevention. Many in vitro models of nonreplicating persistence have been developed to characterize the physiologic and metabolic adaptations of Mtb and identify compounds active against this treatment-recalcitrant population. However, there is little consensus on their relevance to in vivo infection. Using lipid-laden macrophage lysates, we have designed and validated a surrogate matrix that closely mimics caseum and in which Mtb develops a phenotype similar to that of nonreplicating bacilli in vivo. The assay is well suited to screen for bactericidal compounds against caseum-resident Mtb in a medium-throughput format, allowing for reduced reliance on resource intensive animal models that present large necrotic lesions and cavities. Importantly, this approach will aid the identification of vulnerable targets in caseum Mtb and can accelerate the development of novel TB drugs with treatment-shortening potential.
Microfluidics as a Novel Technique for Tuberculosis: From Diagnostics to Drug Discovery

Antonia Molloy,James Harrison,John S. McGrath,Zachary Owen,Clive Smith,Xin Liu,Xin Li,Jonathan A. G. Cox

DOI: https://doi.org/10.3390/microorganisms9112330

IF: 4.5

2021-11-11

Microorganisms

Abstract:Tuberculosis (TB) remains a global healthcare crisis, with an estimated 5.8 million new cases and 1.5 million deaths in 2020. TB is caused by infection with the major human pathogen Mycobacterium tuberculosis, which is difficult to rapidly diagnose and treat. There is an urgent need for new methods of diagnosis, sufficient in vitro models that capably mimic all physiological conditions of the infection, and high-throughput drug screening platforms. Microfluidic-based techniques provide single-cell analysis which reduces experimental time and the cost of reagents, and have been extremely useful for gaining insight into monitoring microorganisms. This review outlines the field of microfluidics and discusses the use of this novel technique so far in M. tuberculosis diagnostics, research methods, and drug discovery platforms. The practices of microfluidics have promising future applications for diagnosing and treating TB.

microbiology
Antibiotic lethality dictates mycobacterial infection outcomes

Alexander Jovanovic,Frederick K. Bright,Ahmad Sadeghi,Basil Wicki,Santiago E.C. Muniz,Sara Toprak,Loic Sauteur,Anna Rodoni,Andreas Wust,Andreanne Lupien,Sonia Borrell,Dorothy M. Grogono,Nicole Wheeler,Philippe Dehio,Johannes Nemeth,Hans Pargger,Rachel Thomson,Scott C. Bell,Sebastien Gagneux,Josephine M. Bryant,Tingying Peng,Andreas Diacon,R. Andres Floto,Michael Abanto,Lucas Boeck

DOI: https://doi.org/10.1101/2024.10.29.619904

2024-10-29

Abstract:Antibiotic development and treatment focus on bacterial growth inhibition, often with limited success. Here, we introduce Antimicrobial Single-Cell Testing (ASCT), an advanced imaging strategy to assess bacterial killing in real-time. By tracking 140 million bacteria and generating over 20,000 in vitro time-kill curves, we can predict Mycobacterium tuberculosis treatment outcomes in mice and humans and link strain-specific survival (drug tolerance) in Mycobacterium abscessus to clinical responses. Using ASCT, we reveal drug tolerance as a distinct genetically encoded bacterial trait conserved across drugs with similar targets and, via genome-wide associations, uncover molecular mechanisms that govern bacterial killing. This study establishes the technical framework and in vivo validation for large-scale bacterial killing assessments to advance our understanding of bacterial survival and enhance antibiotic development and clinical decision-making.

Microbiology
Dynamic microfluidic single-cell screening identifies pheno-tuning compounds to potentiate tuberculosis therapy

Maxime Mistretta,Mena Cimino,Pascal Campagne,Stevenn Volant,Etienne Kornobis,Olivier Hebert,Christophe Rochais,Patrick Dallemagne,Cédric Lecoutey,Camille Tisnerat,Alban Lepailleur,Yann Ayotte,Steven R. LaPlante,Nicolas Gangneux,Monika Záhorszká,Jana Korduláková,Sophie Vichier-Guerre,Frédéric Bonhomme,Laura Pokorny,Marvin Albert,Jean-Yves Tinevez,Giulia Manina

DOI: https://doi.org/10.1038/s41467-024-48269-2

IF: 16.6

2024-05-17

Nature Communications

Abstract:Drug-recalcitrant infections are a leading global-health concern. Bacterial cells benefit from phenotypic variation, which can suggest effective antimicrobial strategies. However, probing phenotypic variation entails spatiotemporal analysis of individual cells that is technically challenging, and hard to integrate into drug discovery. In this work, we develop a multi-condition microfluidic platform suitable for imaging two-dimensional growth of bacterial cells during transitions between separate environmental conditions. With this platform, we implement a dynamic single-cell screening for pheno-tuning compounds, which induce a phenotypic change and decrease cell-to-cell variation, aiming to undermine the entire bacterial population and make it more vulnerable to other drugs. We apply this strategy to mycobacteria, as tuberculosis poses a major public-health threat. Our lead compound impairs Mycobacterium tuberculosis via a peculiar mode of action and enhances other anti-tubercular drugs. This work proves that harnessing phenotypic variation represents a successful approach to tackle pathogens that are increasingly difficult to treat.

multidisciplinary sciences
Experimental platform utilising melting curve technology for detection of mutations in Mycobacterium tuberculosis isolates

Agnieszka Broda,Vlad Nikolayevskyy,Nicki Casali,Huma Khan,Richard Bowker,Gemma Blackwell,Bhakti Patel,James Hume,Waqar Hussain,Francis Drobniewski

DOI: https://doi.org/10.1007/s10096-018-3246-2

Abstract:Tuberculosis (TB) remains one of the most deadly infections with approximately a quarter of cases not being identified and/or treated mainly due to a lack of resources. Rapid detection of TB or drug-resistant TB enables timely adequate treatment and is a cornerstone of effective TB management. We evaluated the analytical performance of a single-tube assay for multidrug-resistant TB (MDR-TB) on an experimental platform utilising RT-PCR and melting curve analysis that could potentially be operated as a point-of-care (PoC) test in resource-constrained settings with a high burden of TB. Firstly, we developed and evaluated the prototype MDR-TB assay using specimens extracted from well-characterised TB isolates with a variety of distinct rifampicin and isoniazid resistance conferring mutations and nontuberculous Mycobacteria (NTM) strains. Secondly, we validated the experimental platform using 98 clinical sputum samples from pulmonary TB patients collected in high MDR-TB settings. The sensitivity of the platform for TB detection in clinical specimens was 75% for smear-negative and 92.6% for smear-positive sputum samples. The sensitivity of detection for rifampicin and isoniazid resistance was 88.9 and 96.0% and specificity was 87.5 and 100%, respectively. Observed limitations in sensitivity and specificity could be resolved by adjusting the sample preparation methodology and melting curve recognition algorithm. Overall technology could be considered a promising PoC methodology especially in resource-constrained settings based on its combined accuracy, convenience, simplicity, speed, and cost characteristics.
Differentially culturable tubercle bacteria as a measure of tuberculosis treatment response

Julian S Peters,Amanda McIvor,Andrea O Papadopoulos,Tshepiso Masangana,Bhavna G Gordhan,Ziyaad Waja,Kennedy Otwombe,Matebogo Letutu,Mireille Kamariza,Timothy R Sterling,Carolyn R Bertozzi,Neil A Martinson,Bavesh D Kana

DOI: https://doi.org/10.3389/fcimb.2022.1064148

2023-01-12

Abstract:Introduction: Routine efficacy assessments of new tuberculosis (TB) treatments include quantitative solid culture or routine liquid culture, which likely miss quantification of drug tolerant bacteria. To improve these assessments, comparative analyses using additional measures such as quantification of differentially culturable tubercle bacteria (DCTB) are required. Essential for enabling this is a comparative measure of TB treatment responses using routine solid and liquid culture with liquid limiting dilutions (LLDs) that detect DCTB in sputum. Methods: We recruited treatment-naïve TB patients, with and without HIV-infection, and serially quantified their sputum for DCTB over the course of treatment. Results: Serial sputum sampling in 73 individuals during their first 14 days of treatment demonstrated that clearance of DCTB was slower compared to routine solid culture. Treatment response appeared to be characterized by four patterns: (1) Classic bi-phasic bacterial clearance; (2) early non-responders with slower clearance; (3) paradoxical worsening with an increase in bacterial count upon treatment initiation; and (4) non-responders with no change in bacterial load. During treatment, LLDs displayed greater bacterial yield when compared with quantitative solid culture. Upon treatment completion, 74% [46/62] of specimens displayed residual DCTB and within this group, two recurrences were diagnosed. Residual DCTB upon treatment completion was associated with a higher proportion of MGIT culture, GeneXpert, and smear positivity at two months post treatment. No recurrences occurred in the group without residual DCTB. Discussion: These data indicate that DCTB assays detect distinct subpopulations of organisms in sputum that are missed by routine solid and liquid culture, and offer important alternatives for efficacy assessments of new TB treatments. The residual DCTB observed upon treatment completion suggests that TB treatment does not always eliminate all bacterial populations, a finding that should be investigated in larger cohorts.
Potential Application of Digitally Linked Tuberculosis Diagnostics for Real-Time Surveillance of Drug-Resistant Tuberculosis Transmission: Validation and Analysis of Test Results

Kamela Charmaine Ng,Conor Joseph Meehan,Gabriela Torrea,Léonie Goeminne,Maren Diels,Leen Rigouts,Bouke Catherine de Jong,Emmanuel André

DOI: https://doi.org/10.2196/medinform.9309

2018-02-27

Abstract:Background: Tuberculosis (TB) is the highest-mortality infectious disease in the world and the main cause of death related to antimicrobial resistance, yet its surveillance is still paper-based. Rifampicin-resistant TB (RR-TB) is an urgent public health crisis. The World Health Organization has, since 2010, endorsed a series of rapid diagnostic tests (RDTs) that enable rapid detection of drug-resistant strains and produce large volumes of data. In parallel, most high-burden countries have adopted connectivity solutions that allow linking of diagnostics, real-time capture, and shared repository of these test results. However, these connected diagnostics and readily available test results are not used to their full capacity, as we have yet to capitalize on fully understanding the relationship between test results and specific rpoB mutations to elucidate its potential application to real-time surveillance. Objective: We aimed to validate and analyze RDT data in detail, and propose the potential use of connected diagnostics and associated test results for real-time evaluation of RR-TB transmission. Methods: We selected 107 RR-TB strains harboring 34 unique rpoB mutations, including 30 within the rifampicin resistance-determining region (RRDR), from the Belgian Coordinated Collections of Microorganisms, Antwerp, Belgium. We subjected these strains to Xpert MTB/RIF, GenoType MTBDRplus v2.0, and Genoscholar NTM + MDRTB II, the results of which were validated against the strains' available rpoB gene sequences. We determined the reproducibility of the results, analyzed and visualized the probe reactions, and proposed these for potential use in evaluating transmission. Results: The RDT probe reactions detected most RRDR mutations tested, although we found a few critical discrepancies between observed results and manufacturers' claims. Based on published frequencies of probe reactions and RRDR mutations, we found specific probe reactions with high potential use in transmission studies: Xpert MTB/RIF probes A, Bdelayed, C, and Edelayed; Genotype MTBDRplus v2.0 WT2, WT5, and WT6; and Genoscholar NTM + MDRTB II S1 and S3. Inspection of probe reactions of disputed mutations may potentially resolve discordance between genotypic and phenotypic test results. Conclusions: We propose a novel approach for potential real-time detection of RR-TB transmission through fully using digitally linked TB diagnostics and shared repository of test results. To our knowledge, this is the first pragmatic and scalable work in response to the consensus of world-renowned TB experts in 2016 on the potential of diagnostic connectivity to accelerate efforts to eliminate TB. This is evidenced by the ability of our proposed approach to facilitate comparison of probe reactions between different RDTs used in the same setting. Integrating this proposed approach as a plug-in module to a connectivity platform will increase usefulness of connected TB diagnostics for RR-TB outbreak detection through real-time investigation of suspected RR-TB transmission cases based on epidemiologic linking.
UV/H(2)O(2) treatment of drinking water increases post-chlorination DBP formation.

A. Dotson,Volha Olya S Keen,D. Metz,K. Linden

DOI: https://doi.org/10.1016/j.watres.2010.04.006

IF: 12.8

2010-06-01

Water Research

Abstract:
Development and application of the direct mycobacterial growth inhibition assay: a systematic review

Hannah Painter,Eli Harriss,Helen A. Fletcher,Helen McShane,Rachel Tanner

DOI: https://doi.org/10.3389/fimmu.2024.1355983

IF: 7.3

2024-02-06

Frontiers in Immunology

Abstract:Introduction First described by Wallis et al. in 2001 for the assessment of TB drugs, the direct mycobacterial growth inhibition assay (MGIA) offers a tractable ex vivo tool measuring the combined influences of host immunity, strain virulence and intervention effects. Over the past 13 years, we have led efforts to adapt the direct MGIA for the assessment of TB vaccines including optimisation, harmonisation and validation of BCG vaccine-induced responses as a benchmark, as well as assay transfer to institutes worldwide. Methods We have performed a systematic review on the primary published literature describing the development and applications of the direct MGIA from 2001 to June 2023 in accordance with the PRISMA reporting guidelines. Results We describe 63 studies in which the direct MGIA has been applied across species for the evaluation of TB drugs and novel TB vaccine candidates, the study of clinical cohorts including those with comorbidities, and to further understanding of potential immune correlates of protection from TB. We provide a comprehensive update on progress of the assay since its conception and critically evaluate current findings and evidence supporting its utility, highlighting priorities for future directions. Discussion While further standardisation and validation work is required, significant advancements have been made in the past two decades. The direct MGIA provides a potentially valuable tool for the early evaluation of TB drug and vaccine candidates, clinical cohorts, and immune mechanisms of mycobacterial control. Systematic review registration https://www.crd.york.ac.uk/prospero/ , identifier CRD42023423491.

immunology
One-day phenotypic drug susceptibility testing for Mycobacterium tuberculosis variant bovis BCG using single-cell imaging and a deep neural network

Buu Minh Tran,Jimmy Larsson,Anastasia Grip,Praneeth Karempudi,Johan Elf

DOI: https://doi.org/10.1101/2024.05.20.594971

2024-05-20

Abstract:Drug-resistant tuberculosis (TB) kills approximately 200,000 people every year. A contributing factor is the slow turnaround time associated with anti-tuberculosis drug susceptibility diagnostics. The prevailing gold standard for phenotypic drug susceptibility testing (pDST) takes at least two weeks. In this study, we used Mycobacterium tuberculosis variant bovis BCG (M. bovis BCG) and Mycobacterium smegmatis as models for tuberculous and nontuberculous pathogens. The bacteria were loaded into a microfluidic chip, trapping them in microchambers, and allowing simultaneous tracking of single-cell growth with and without antibiotic exposure. A deep neural network image-segmentation algorithm was employed to quantify the growth rate over time and determine how the strains responded to the drugs compared to the untreated reference. We determined that the response time of the susceptible strains to isoniazid (INH), ethambutol (EMB), and linezolid (LZD) at MIC was within 3 hours and 1.5 hours for M. bovis BCG and M. smegmatis, respectively. Resistant strains of M. smegmatis were identifiable within 3 hours, suggesting that growth-based pDST can be conducted in less than 12 hours for slow-growing M. bovis BCG. The results obtained for M. bovis BCG are most likely comparable to what we expect for M. tuberculosis as these strains share 99.96% genetic identity.

Microbiology
High-throughput nanopore targeted sequencing for efficient drug resistance assay of Mycobacterium tuberculosis

Chen Tang,Lianpeng Wu,Machao Li,Jianyi Dai,Ye Shi,Qiongdan Wang,Feng Xu,Laibao Zheng,Xingxing Xiao,Junwen Cai,Yanjun Zhang,Yuting Yang,Xiaoqun Zheng,Guangxin Xiang

DOI: https://doi.org/10.3389/fmicb.2024.1331656

IF: 5.2

2024-05-23

Frontiers in Microbiology

Abstract:Drug-resistant tuberculosis (TB), especially multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB), is one of the urgent clinical problems and public health challenges. Culture-based phenotypic drug susceptibility testing (pDST) is time-consuming, and PCR-based assays are limited to hotspot mutations. In this study, we developed and validated a convenient and efficient approach based on high-throughput nanopore sequencing technology combined with multiplex PCR, namely nanopore targeted sequencing (NTS), to simultaneously sequence 18 genes associated with antibiotic resistance in Mycobacterium tuberculosis (MTB). The analytical performance of NTS was evaluated, and 99 clinical samples were collected to assess its clinical performance. The NTS results showed that MTB and its drug resistance were successfully identified in approximately 7.5 h. Furthermore, compared to the pDST and Xpert MTB/RIF assays, NTS provided much more drug resistance information, covering 14 anti-TB drugs, and it identified 20 clinical cases of drug-resistant MTB. The mutations underlying these drug-resistant cases were all verified using Sanger sequencing. Our approach for this TB drug resistance assay offers several advantages, including being culture-free, efficient, high-throughput, and highly accurate, which would be very helpful for clinical patient management and TB infection control.

microbiology
The – infection model, a powerful high throughput screening platform for anti-infective compounds

Jahn Nitschke,Nabil Hanna,Thierry Soldati

DOI: https://doi.org/10.1101/2024.12.03.626613

2024-12-03

Abstract:Tuberculosis is among the world's deadliest diseases, causing approximately 2 million deaths annually. The urgent need for new antitubercular drugs has been intensified by the rise of drug-resistant strains. Despite recent advancements, most hits identified through traditional target-based screening exhibit limited efficacy . Consequently, there is a growing demand for whole-cell-based approaches that directly utilize host–pathogen systems. The – host–pathogen system is a well-established and powerful alternative model system to study mycobacterial infections. In this article, the phenotypic host-pathogen protocol assay is presented here which relies on monitoring during its infection of the amoeba . This assay is characterized by its scalability for high-throughput screening, robustness, and ease of manipulation, making it an effective system for compound screening. This system provides not only bacterial load readout via a bioluminescent strain, but now also host survival and growth via a fluorescent strain enabling further host characterization by quantifying growth inhibition and potential cytotoxicity. Finally, the system was benchmarked with selected antibiotics and anti-infectives and calculated IC50s and MICs where applicable, demonstrating its capability to differentiate between antibiotics and anti-infective compounds.

Microbiology
State-of-the-art detection of Mycobacterium tuberculosis in blood during tuberculosis infection using phage technology

Catherine Ed Rees,Benjamin Mc Swift,Pranabashis Haldar,Catherine ED Rees,Benjamin MC Swift

DOI: https://doi.org/10.1016/j.ijid.2024.106991

IF: 12.073

2024-03-23

International Journal of Infectious Diseases

Abstract:Introduction/ Tuberculosis (TB), an aerosol-transmitted infection caused by Mycobacterium tuberculosis ( Mtb) , remains the commonest cause of death globally, from an infectious bacterial disease. Nine years on from the launch of the World Health Organization (WHO)'s END-TB strategy, disease incidence rates are stubbornly unchanged [1] . While this represents, in part, a reversal of improving trends caused by the COVID-19 pandemic, it also reflects the fragility and inadequacy of healthcare systems to sustain TB control [2] . Although multifactorial, a key reason for this is the ineffectiveness of existing clinical tools to meet the two key objectives of the END-TB strategy—(i) early diagnosis and treatment of TB disease (to limit onward transmission); and (ii) disease prevention through screening for asymptomatic TB infection (TBI). Meeting both objectives will rely on the development of new biomarkers with high accuracy, but the global nature of the TB problem also requires that new tests are rapid, low cost and can be measured in patients by sampling from universally accessible sites. In this review, we will present the accumulating evidence for circulating Mtb in both TB disease and asymptomatic TBI and discuss the potential utility of novel bacteriophage-based technology for blood-based detection of Mtb.

infectious diseases
Construction of an overexpression library for Mycobacterium tuberculosis

Eduard Melief,Rachel Kokoczka,Megan Files,Mai Ann Bailey,Torey Alling,Hongye Li,James Ahn,Ayesha Misquith,Aaron Korkegian,David Roberts,James Sacchettini,Tanya Parish

DOI: https://doi.org/10.1093/biomethods/bpy009

2018-01-01

Biology Methods and Protocols

Abstract:Abstract There is a pressing need to develop novel anti-tubercular drugs. High-throughput phenotypic screening yields chemical series that inhibit bacterial growth. Target identification for such series is challenging, but necessary for optimization of target engagement and the development of series into clinical drugs. We constructed a library of recombinant Mycobacterium tuberculosis strains each expressing a single protein from an inducible promoter as a tool for target identification. The library of 1733 clones was arrayed in 96-well plates for rapid screening and monitoring growth. The library contains the majority of the annotated essential genes as well as genes involved in cell wall and fatty acid biosynthesis, virulence factors, regulatory proteins, efflux, and respiration pathways. We evaluated the growth kinetics and plasmid stability over three passages for each clone in the library. We determined expression levels (mRNA and/or protein) in 396 selected clones. We screened the entire library and identified the Alr-expressing clone as the only recombinant strain, which grew in the presence of d-cycloserine (DCS). We confirmed that the Alr-expressing clone was resistant to DCS (7-fold shift in minimum inhibitory concentration). The library represents a new tool that can be used to screen for compound resistance and other phenotypes.

biology

Stabilization strategies for unstable dynamics.

Identification of Host-Targeted Small Molecules That Restrict Intracellular Mycobacterium tuberculosis Growth

Identification of bioactive compounds Inhibitors of M. tuberculosis Growth Using Whole Cell Based High-Throughput Screening

Vascular Management During Live Donor Nephrectomy: An Online Survey Among Transplant Surgeons

Radiographic Comparison of Standing Medial Cuneiform Arch Height in Adults With and Without Acquired Flatfoot Deformity

Rapid Gene Silencing Followed by Antimicrobial Susceptibility Testing for Target Validation in Antibiotic Discovery

A high-throughput target-based screening approach for the identification and assessment of Mycobacterium tuberculosis mycothione reductase inhibitors

A Novel Tool to Identify Bactericidal Compounds against Vulnerable Targets in Drug-Tolerant M. tuberculosis found in Caseum

Microfluidics as a Novel Technique for Tuberculosis: From Diagnostics to Drug Discovery

Antibiotic lethality dictates mycobacterial infection outcomes

Dynamic microfluidic single-cell screening identifies pheno-tuning compounds to potentiate tuberculosis therapy

Experimental platform utilising melting curve technology for detection of mutations in Mycobacterium tuberculosis isolates

Differentially culturable tubercle bacteria as a measure of tuberculosis treatment response

Potential Application of Digitally Linked Tuberculosis Diagnostics for Real-Time Surveillance of Drug-Resistant Tuberculosis Transmission: Validation and Analysis of Test Results

UV/H(2)O(2) treatment of drinking water increases post-chlorination DBP formation.

Development and application of the direct mycobacterial growth inhibition assay: a systematic review

One-day phenotypic drug susceptibility testing for Mycobacterium tuberculosis variant bovis BCG using single-cell imaging and a deep neural network

High-throughput nanopore targeted sequencing for efficient drug resistance assay of Mycobacterium tuberculosis

The – infection model, a powerful high throughput screening platform for anti-infective compounds

State-of-the-art detection of Mycobacterium tuberculosis in blood during tuberculosis infection using phage technology

Construction of an overexpression library for Mycobacterium tuberculosis